New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.71 0.14 +0.51%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Pfizer Inc. (PFE) Earnings & Analysis

Updated · Covers results through Q3 FY2026 · Earnings call · Latest filing 10-Q filed Nov 3, 2026 · How this is made

Latest quarter

Pfizer reported Q3 FY2026 revenue of $16.6 billion, above the consensus estimate of $16.1 billion but below the $16.7 billion reported a year earlier. Adjusted earnings per share were $0.87, compared with the consensus estimate of $0.72.

In its filing, Pfizer attributed the year-over-year revenue decline to COVID-19 products, the Prevnar vaccine family and other products, largely offset by growth in Eliquis, Padcev, the Vyndaqel family and other medicines. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally. Pfizer attributed Eliquis growth primarily to higher U.S. net pricing and global demand, while it linked the Prevnar decline to lower vaccination rates and U.S. adult market-share erosion.

Pfizer reported diluted EPS of $0.57, down from $0.62 a year earlier. Gross margin rose to 75.7% from 74.9%, while operating margin declined to 22.1% from 23.1%. Free cash flow increased to $4.8 billion from $4.0 billion.

Q3 FY2026 Q3 FY2025 Change
Revenue $16.6 billion $16.7 billion −0.43%
Diluted EPS $0.57 $0.62 −8.79%
Gross margin 75.7% 74.9% 0.8 percentage points
Operating margin 22.1% 23.1% −1.0 percentage point
Free cash flow $4.8 billion $4.0 billion 20.0%
Against the consensus Reported Consensus Result
Adjusted EPS $0.87 $0.72 Beat by 20.8%
Revenue $16.6 billion $16.1 billion Beat by 2.80%

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

What management said on the call

CEO Albert Bourla said launched and acquired products grew 32% operationally in the quarter. He said acquired products grew 37% operationally, while the legacy Seagen portfolio grew 39% year over year in the U.S., driven by Padcev.

CFO Cecile Guegan said launched and acquired products contributed $3.8 billion in quarterly revenue. She said non-COVID products grew 7% operationally, offset by lower COVID-19 product revenue. Guegan attributed the quarter’s adjusted gross margin of 77% primarily to product mix and cost management; she said the adjusted operating margin was 36%, tempered by the Innovent acquired research and development charge.

Asked about pricing, Guegan said quarterly performance was driven mostly by market performance and volume rather than changes in gross-to-net pricing. She noted an exception for Eliquis, where the effect of a January wholesale price decrease began in the third quarter. Bourla said Pfizer saw international opportunity for its oral migraine treatments while managing competition.

On investment, Bourla said Pfizer had made progress enrolling patients in its obesity studies. He said, “We are working toward the first in a series of potential approvals for berobenatide in 2028.” Executive Chris Boshoff said the Phase 2b amylin combination study was fully recruited and its efficacy readout was expected in the second half of 2027.

Asked about savings, Guegan said Pfizer expected its next phase of cost programs to mitigate margin erosion during the 2027–2029 loss-of-exclusivity transition. She said the company would provide 2027 guidance around the middle of December, with patent expirations, product launches, pricing and cost initiatives among the factors it would consider.

Guidance

Pfizer raised its FY2026 revenue guidance to $62.0 billion–$64.0 billion from $60.5 billion–$62.5 billion. It also raised and narrowed its adjusted diluted EPS outlook to $2.95–$3.05 from $2.80–$3.00. Guegan said the updated EPS range absorbed the $0.10 per-share impact of the Innovent transaction.

Metric For Guide Previous guide Change
Operating expenses, Si and A Non Gaap FY2026 Pfizer expects FY2026 SI&A expenses to decline from the prior year. — —
Gross margin, non-GAAP FY2026 Pfizer expects FY2026 adjusted gross margin in the mid-70% range. — —
EPS, non-GAAP FY2026 $2.95–$3.05 $2.80–$3.00 Raised
Research and development, non-GAAP FY2026 $10.8 billion–$11.8 billion — New
Share repurchases FY2026 Pfizer does not anticipate share repurchases in FY2026. Pfizer does not anticipate share repurchases in 2026. —
Revenue FY2026 $62.0 billion–$64.0 billion $60.5 billion–$62.5 billion Raised
Tax rate, non-GAAP FY2026 15.0% — New
Revenue, Covid-19 products FY2026 $4.0 billion — New
EPS, Adjusted Diluted FY2026 $0.10 — —
Revenue, Covid 19 FY2026 $4.0 billion — New
Units, Research and Development FY2026 20 — —
EPS FY2026 $2.80–$3.00 — New